Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Firebrick Pharma Limited ( (AU:FRE) ) has shared an announcement.
Firebrick Pharma Limited has secured an additional investment of $102,000 from its strategic partner Pharma Nutria N.A., Inc. (PNAI) in the Philippines. This investment, made at a 31% premium over the previous closing price, aims to restore PNAI’s holding to above 5% following a recent placement to other investors. The move underscores PNAI’s confidence in Firebrick’s leadership and the potential of its product Nasodine, with the partnership expected to enhance Firebrick’s market presence in the Philippines.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has developed Nasodine Nasal Spray (0.5% PVP-I) and is working on other products. Firebrick has launched Nasodine in the United States, Singapore, and Fiji & South Pacific, with plans to enter the Philippine market in 2026.
Average Trading Volume: 71,722
Technical Sentiment Signal: Sell
For an in-depth examination of FRE stock, go to TipRanks’ Overview page.